World Journal of Pharmaceutical
and Medical Research

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical and Medical Research and Technology
An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)
ISSN 2455-3301
IMPACT FACTOR: 6.842

ICV : 78.6

World Journal of Pharmaceutical and Medical Research (WJPMR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Indian Science Publications , Cosmos Impact Factor , Research Bible, Fuchu, Tokyo. JAPAN , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , International Innovative Journal Impact Factor (IIJIF) , Scientific Journal Impact Factor (SJIF) , Global Impact Factor (In Process) , Digital Online Identifier-Database System (DOI-DS) , Science Library Index, Dubai, United Arab Emirates , Eurasian Scientific Journal Index (ESJI) , International Scientific Indexing, (ISI) UAE , IFSIJ Measure of Journal Quality , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

Abstract

PREDICTION OF MORTALITY AND TRANSFER TO ICU BASED ON ABNORMAL LIVER FUNCTION TESTS IN PATIENTS HOSPITALIZED WITH COVID-19 IN A TERTIARY CARE CENTRE (SOUTH- INDIA)

C.G. Sridhar*, Anabhra Sharma, Soundappan Somasundaram, Shikha Sharma, Mohd. Juned Khan, Raghunath D., Dhivahar G. and Aravinth S.

ABSTRACT

Background: The pandemic of coronavirus (COVID-19) has rapidly emerged as a relevant threat for humans worldwide. The main clinical feature is pneumonia characterized by a high mortality rate, however, increasing data suggest that COVID-19 is a systemic disease affecting other organs/systems including liver, kidney and coagulation system and heart.[2-5] An increase in liver function tests (LFTs) (14%-75% of hospitalized patients in the world) has been found in patients with COVID-19.[2,3,6-11] Aim of this study was to assess the prevalence and the clinical impact of abnormal LFTs in hospitalized COVID-19 patients to predict mortality. Methodology: Patients hospitalized between 1/5/21 to 25/5/21 in COVID-Unit of GEM Hospital and research centre were retrospectively identified. Inclusion criteria were as follows: (a) patients hospitalized with a SARS-CoV-2 infection confirmed by real-time reverse transcription polymerase chain reaction method; (b) age >12 years old. Exclusion criterion involve patients admitted to ICU within 6 hours of admission as they were likely to be critically ill at admission with other unknown comorbidities and we wanted to target patients managed in regular wards so that a prediction model can be studied for future admissions. Verbal or written informed consent was taken and study approval permission given by local Ethics Committee. The study was performed according to the Institutional ethical guidelines and according to the principles of Declaration of Helsinki (Seventh edition). Results: Median age was 52 years with more prevalence in men (58.5%). All patients reported flu-like symptoms: fever (137 [77.8%]), cough (116 [65.9%]), fatigue (55 [31.3%]) and muscle pain (15 [8.5%]); gastrointestinal symptoms were observed in 39 patients (22.2%). Dyspnoea was present in 73 (41.5%) patients. At least one co-morbidity was recognised in about 43% of positive patients. Among the total admitted patients, 44 (25%) patients were shifted to ICU in need for either ventilatory support or hemodynamic instability and this was significantly associated with patients having SIRS, high CRP & D-Dimer values (p-value =0.001). The final outcome in any form was seen to be significantly associated with COVID profile of the patient (raised CRP with p-value =0.002) and no significant association was seen between in hospital mortality and LFT derangement of a patient. Conclusion: LFT abnormalities are common at admission in patients with COVID-19, but it cannot be used as an independent predictor of transfer to ICU or death unlike other markers of systemic inflammation and multi-organ dysfunction. Lay summary: Liver test abnormalities (in particular elevations in the levels of aspartate aminotransferase [AST], alanine aminotransferase [ALT] and total bilirubin [T-Bil]) were observed commonly after symptom onset in patients who were admitted with coronavirus disease 2019 (COVID-19). Abnormal levels of these liver function tests cannot be used as an independent predictors of COVID-19 related mortality and morbidity.

[Full Text Article]    [Download Certificate]

Powered By WJPMR | All Right Reserved

WJPMR